We are live on ! Find out more
KNSA icon

Kiniksa Pharmaceuticals
KNSA

134 hedge funds and large institutions have $606M invested in Kiniksa Pharmaceuticals in 2023 Q3 according to their latest regulatory filings, with 19 funds opening new positions, 49 increasing their positions, 43 reducing their positions, and 11 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% more funds holding in top 10

Funds holding in top 10: 1 → 2 (+1)

73% more first-time investments, than exits

New positions opened: 19 | Existing positions closed: 11

35% more capital invested

Capital invested by funds: $448M → $606M (+$158M)

14% more repeat investments, than reductions

Existing positions increased: 49 | Existing positions reduced: 43

13% more call options, than puts

Call options by funds: $5.21M | Put options by funds: $4.6M

8.04% more ownership

Funds ownership: 90.92% → 98.97% (+8%)

6% more funds holding

Funds holding: 127 → 134 (+7)

Holders
134
Holders Change
+7
Holders Change %
+5.51%
% of All Funds
2.13%
Holding in Top 10
2
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+100%
% of All Funds
0.03%
New
19
Increased
49
Reduced
43
Closed
11
Calls
$5.21M
Puts
$4.6M
Net Calls
+$605K
Net Calls Change
-$496K

Top Buyers

1
FFM
Fairmount Funds Management
Pennsylvania
+$29.8M
2
DCM
Driehaus Capital Management
Illinois
+$8.49M
3
Goldman Sachs
Goldman Sachs
New York
+$8.33M
4
N
Nuveen
North Carolina
+$7.58M
5
Millennium Management
Millennium Management
New York
+$4.6M

Top Sellers

1
Hudson Bay Capital Management
Hudson Bay Capital Management
Connecticut
-$6.36M
2
SCM
Soleus Capital Management
Connecticut
-$6.1M
3
Allspring Global Investments
Allspring Global Investments
North Carolina
-$5.15M
4
RCMNY
Rubric Capital Management (New York)
New York
-$5.07M
5
WP
Woodline Partners
California
-$4.08M
Name Holding Trade Value Shares
Change 		Change in
Stake
BlackRock
1
BlackRock
New York
$54.2M -$710K -42,116 -1%
RCMNY
2
Rubric Capital Management (New York)
New York
$53.5M -$5.07M -300,715 -9%
Vanguard Group
3
Vanguard Group
Pennsylvania
$51.4M -$2.16M -128,255 -4%
BBA
4
Baker Bros. Advisors
New York
$48.8M – – –
FFM
5
Fairmount Funds Management
Pennsylvania
$43M +$29.8M +1,770,102 +251%
State Street
6
State Street
Massachusetts
$30.6M +$1.85M +109,701 +7%
Pictet Asset Management
7
Pictet Asset Management
Switzerland
$27.9M +$27M +1,604,717 New
Morgan Stanley
8
Morgan Stanley
New York
$25.9M +$3.08M +182,746 +14%
Goldman Sachs
9
Goldman Sachs
New York
$15M +$8.33M +494,264 +133%
ACH
10
ArrowMark Colorado Holdings
Colorado
$13.2M -$3.79M -224,843 -23%
HA
11
HHLR Advisors
Cayman Islands
$12.1M – – –
Geode Capital Management
12
Geode Capital Management
Massachusetts
$11.5M +$790K +46,917 +8%
RHJA
13
Rice Hall James & Associates
California
$11.3M -$164K -9,758 -1%
Millennium Management
14
Millennium Management
New York
$10.5M +$4.6M +272,828 +82%
TCM
15
Tang Capital Management
California
$10.4M – – –
N
16
Nuveen
North Carolina
$9.8M +$7.58M +450,181 +396%
GIM
17
Granahan Investment Management
Massachusetts
$9.28M -$37.3K -2,215 -0.4%
PHP
18
Parkman Healthcare Partners
Connecticut
$8.86M +$3.67M +218,107 +75%
DCM
19
Driehaus Capital Management
Illinois
$8.75M +$8.49M +503,750 New
GC
20
GMT Capital
Georgia
$8.3M +$3.01M +178,609 +60%
Dimensional Fund Advisors
21
Dimensional Fund Advisors
Texas
$6.49M -$23.4K -1,388 -0.4%
Ameriprise
22
Ameriprise
Minnesota
$6.03M -$411K -24,408 -7%
AQR Capital Management
23
AQR Capital Management
Connecticut
$5.62M -$3.16M -187,444 -37%
D.E. Shaw & Co
24
D.E. Shaw & Co
New York
$5.52M +$1.33M +78,919 +33%
Hudson Bay Capital Management
25
Hudson Bay Capital Management
Connecticut
$5.25M -$6.36M -377,500 -56%
1
2 3 4 5

KNSA Hedge Fund Activity: Q3 2023 in Review

134 of the 6,301 institutional investors tracked by Wall St. Rank reported a position in Kiniksa Pharmaceuticals (KNSA) for Q3 2023, worth a combined $606M — up 35% from $448M a quarter earlier.

Buyers outnumbered sellers: 19 funds opened new KNSA positions and 11 closed out — a net gain of 8 holders — while 49 added to existing stakes and 43 trimmed.

The largest buyer was Fairmount Funds Management, adding an estimated $29.8M. The largest seller was Hudson Bay Capital Management, cutting an estimated $6.36M.

  • 134 institutional investors held Kiniksa Pharmaceuticals (KNSA) as of Q3 2023, up from 127 in Q2 2023.
  • Funds reported $606M of Kiniksa Pharmaceuticals stock for Q3 2023, up 35% quarter-over-quarter.
  • 19 funds opened new Kiniksa Pharmaceuticals positions in Q3 2023 and 11 closed out, a net change of +8 holders.
  • The largest Kiniksa Pharmaceuticals buyer in Q3 2023 was Fairmount Funds Management, an estimated $29.8M added.
  • The largest Kiniksa Pharmaceuticals seller in Q3 2023 was Hudson Bay Capital Management, an estimated $6.36M sold.

Based on aggregated 13F filings for Q3 2023.